ID   DL-40
AC   CVCL_2889
SY   DL40
DR   cancercelllines; CVCL_2889
DR   Cell_Model_Passport; SIDM01506
DR   DepMap; ACH-001060
DR   GEO; GSM2527953
DR   JCRB; JCRB1337
DR   JCRB; NIHS0542
DR   Wikidata; Q54831137
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1979248;
RX   PubMed=8957066;
RX   PubMed=10639591;
RX   PubMed=15356658;
RX   PubMed=28356514;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: 72 hours (PubMed=1979248).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Unspecified (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Discontinued: JCRB; NIHS0542; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): JCRB
ST   Amelogenin: X
ST   CSF1PO: 13,14
ST   D13S317: 9,13
ST   D16S539: 10,11
ST   D5S818: 9,12
ST   D7S820: 10,11
ST   TH01: 8
ST   TPOX: 8,9
ST   vWA: 14,19
DI   NCIt; C37194; Anaplastic large cell lymphoma, ALK-negative
DI   ORDO; Orphanet_300903; ALK-negative anaplastic large cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   64Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 19
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1979248;
RA   Kubonishi I., Sonobe H., Miyagi T., Iwahara Y., Ohyashiki J.H.,
RA   Ohyashiki K., Toyama K., Ohtsuki Y., Miyoshi I.;
RT   "A Ki-1 (CD30)-positive T (E+, CD4+, Ia+)-cell line, DL-40,
RT   established from aggressive large cell lymphoma.";
RL   Cancer Res. 50:7682-7685(1990).
//
RX   PubMed=8957066; DOI=10.1111/j.1349-7006.1996.tb03112.x;
RA   Kawasaki N., Matsuo Y., Yoshino T., Yanai H., Oka T., Teramoto N.,
RA   Liu C., Kondo E., Minowada J., Akagi T.;
RT   "Metastatic potential of lymphoma/leukemia cell lines in SCID mice is
RT   closely related to expression of CD44.";
RL   Jpn. J. Cancer Res. 87:1070-1077(1996).
//
RX   PubMed=10639591; DOI=10.3892/ijmm.5.2.139;
RA   Ogawa Y., Nishioka A., Inomata T., Kataoka S., Nakayama K.-i.,
RA   Kariya S., Terashima M., Kubonishi I., Yoshida S.;
RT   "Ionizing radiation-induced apoptosis in human lymphoma cell lines
RT   differing in p53 status.";
RL   Int. J. Mol. Med. 5:139-143(2000).
//
RX   PubMed=15356658; DOI=10.1038/sj.leu.2403465;
RA   Drexler H.G., MacLeod R.A.F.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   anaplastic large-cell lymphoma.";
RL   Leukemia 18:1569-1571(2004).
//
RX   PubMed=28356514; DOI=10.1073/pnas.1700682114;
RA   Chen J., Zhang Y., Petrus M.N., Xiao W.-M., Nicolae A., Raffeld M.,
RA   Pittaluga S., Bamford R.N., Nakagawa M., Ouyang S.T.-Y., Epstein A.L.,
RA   Kadin M.E., Del Mistro A., Woessner R.D., Jaffe E.S., Waldmann T.A.;
RT   "Cytokine receptor signaling is required for the survival of ALK-
RT   anaplastic large cell lymphoma, even in the presence of JAK1/STAT3
RT   mutations.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:3975-3980(2017).
//